Oct 08, 2019

Biopharma Firm Continues to Build Industry Leading Management Team; Poised for Next Phase of Growth in Therapeutic Toxin Market

NEWPORT BEACH, Calif., October 1, 2019 – AEON Biopharma, an emerging biopharma company established to independently pursue the rapidly growing, multi-billion-dollar therapeutic toxin market, announced that it has named Chris Carr as Chief Financial Officer and Scott Akamine as General Counsel.
As AEON Biopharma’s newly appointed Chief Financial Officer, Chris Carr brings over 25 years of financial experience in the pharmaceutical and biotech industries. Mr. Carr most recently served as Chief Financial Officer, Executive Vice President of Finance and IT and Board Member of Dendreon Pharmaceuticals where he served as a key member of the Executive Leadership team, developing and directing the company’s financial and IT business processes and overall business strategy. Prior to his time at Dendreon, Mr. Carr has held financial management positions across the pharmaceutical and biotech industries including Abbott Laboratories, PerkinElmer and Genzyme Corporation.

Scott Akamine joins AEON Biopharma as General Counsel with over 10 years of legal experience in guiding growth strategies through complex legal and regulatory landscapes. Most recently, Mr. Akamine was Vice President and Associate General Counsel at Corelogic where he played a critical role in legal department operations, corporate development and SEC reporting and governance. Prior to CoreLogic, Mr. Akamine held legal management positions at Incipio and Allergan, and was also a Corporate Securities and M&A Attorney at Latham & Watkins.

“AEON Biopharma is uniquely positioned as the only company focused solely on the therapeutic uses of neurotoxins at a time where this already large market is set for incredible growth and I am pleased that Chris Carr and Scott Akamine have joined our management team to help lead our successful trajectory in the market,” said Marc Forth, President and Chief Executive Officer of AEON Biopharma. “Chris’s deep domain expertise in finance and the pharmaceutical and biotech industries, as well as his insights into market economics and trends will only help continue this momentum. Scott’s extensive expertise in legal and regulatory strategy will be vital in supporting AEON Biopharma’s client relationships and overall growth.”

“I am thrilled to join AEON Biopharma at this key stage in the company’s evolution. This is an incredible opportunity and I look forward to working with the team to build Aeon Biopharmaceuticals into a global leader in the therapeutics toxin market” said Chris Carr.
Scott Akamine said, “I am excited to join AEON Biopharma and work alongside the great team Marc has assembled as we continue to break new ground as the only company solely dedicated to the therapeutic applications of toxins.”

About AEON Biopharma, Inc.
AEON Biopharma is a biopharma company dedicated to bringing advanced therapeutic procedures and treatments to physicians. AEON Biopharma is focused on developing an injectable 900 kDa purified botulinum toxin type A complex for therapeutic indications. For more information on the company, please visit www.aeonbiopharma.com.